ReviewStem cells translational medicine2026
Bone tissue regeneration: role of osteocyte mechanosensing and mechanotransduction.
Review in Stem cells translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Critical-sized bone defects caused by trauma, tumor resection, injury, and/or surgical intervention are posing significant clinical challenges. Bone tissue regeneration is crucial for restoring critical-sized bone defects. Central to the bone regenerative capability is the dynamic interplay between bone cells, particularly osteocytes, which are the most abundant and long-lived bone cells, functioning as key mechanosensors in bone. Osteocytes detect mechanical stimuli, for example, fluid shear stress, compressive or tensile strain, and hydrostatic pressure, and convert these into biochemical signals through mechanotransduction. The biochemical signals (eg, calcium ions, Wnt, etc.) regulate osteoblast and osteoclast-mediated remodeling. Osteocytes communicate with osteoblasts and osteoclasts via paracrine factors, including nitric oxide, prostaglandins, and sclerostin. Moreover, estrogen deficiency is known to alter osteocyte mechanosensitivity, impair osteocyte signaling, and dysregulate bone remodeling. Understanding how mechanical and hormonal factors affect osteocyte signaling is essential for developing effective therapeutic interventions. This concise review explores the role of osteocyte mechanosensing and mechanotransduction in bone tissue regeneration to improve bone healing, especially in critical-sized bone defects. The cellular and molecular mechanisms underlying bone regeneration and remodeling are discussed, including the role of stem cells in bone regeneration, that is, osteogenic differentiation potential and secretion of bioactive factors that promote new bone formation and vascularization. Finally, we explore the translational and clinical implications of osteocyte mechanobiology, discussing current challenges and potential advancements in bone tissue engineering and regenerative medicine. By integrating fundamental mechanobiological principles with clinical strategies, this concise review highlights the clinical potential of modulating osteocyte behavior for improved bone regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.